Intermittent presumptive treatment (IPT) in pregnancy involves giving a curative treatment dose of an effective antimalarial drug at predefined intervals during pregnancy. IPT in pregnancy was first introduced in areas of high malaria transmission as a measure to reduce the adverse impact of Plasmodium falciparum malaria in pregnancy [1,2,3,4,5,6,7,8]. Later, based on trials showing that IPT could reduce anaemia in young children and also malaria episodes in infants, it was extended as a measure to reduce morbidity and mortality in the first year of life [9,10,11,12].

Antimalarial chemoprophylaxis for pregnant women living in endemic areas has been recommended for many years, but in practice has been limited to the use of chloroquine and pyrimethamine [13,14]. Unfortunately, there are few places left in the world where these drugs can still be relied upon to prevent P. falciparum malaria. There are insufficient safety data on the newer antimalarials to warrant their systematic use in pregnant women. IPT with sulphadoxine-pyrimethamine (SP) has been introduced as an alternative. Antimalarial chemoprophylaxis in young children has been shown to reduce the adverse impact of P. falciparum malaria [15,16,17], but this intervention never obtained the same endorsement as chemoprophylaxis in pregnancy.

Five randomised trials of IPT in pregnancy in East Africa have been reported [1,2,3,4,5], all with SP, all in high-transmission settings, and all done between 1992 and 1999 (Table S1). The alarming recent increase in resistance to SP in Africa confounds the cost-effectiveness assessments upon which subsequent policy recommendations for IPT in pregnancy were based [18,19].

There is no consensus on how IPT works, making planning difficult. This article argues that IPT provides intermittent suppressive chemoprophylaxis (as opposed to treatment effect alone or some other magical effects which have never been specified). If this is correct dosing schedules should be individualised for each antimalarial depending on the drug’s pharmacokinetic and pharmacodynamic properties. As increasing resistance to SP must seriously compromise IPT regimens based on this drug, the evaluation of available new effective antimalarials is needed urgently, in both high- and low-transmission areas.

Pharmacokinetics

After a treatment dose of SP (25 mg sulfadoxine/1.25 mg pyrimethamine per kilogram body weight), plasma concentrations of pyrimethamine (half-life, 3 days) and sulfadoxine (half-life, 7 days) decline log-linearly [20,21]. The antimalarial effect depends on synergy between the two components, but the effect from one treatment dose can last as long as 60 days with fully sensitive P. falciparum [20,21]. For slowly eliminated antimalarial drugs (Table S2), the terminal elimination phase crosses the in vivo dose–response curve (Figure 1).

Thus, if a full treatment dose is given, concentrations at the beginning of the terminal elimination phase exceed the minimum parasiticidal concentrations (MPCs)—the lowest concentrations that give maximum effect [22]. The exceptions to this are chloroquine (and probably piperaquine), as resistance to these drugs increases, because the elimination of chloroquine is multiexponential, and the terminal elimination phase begins at concentrations that are low by comparison with the peak concentrations after treatment (Figure 2).

The pharmacokinetic properties of many drugs are altered in pregnancy; lower concentrations often result from an expanded volume of distribution. Strangely, despite the wide endorsement of SP IPT in pregnancy, there are no pharmacokinetic studies...
of sulphadoxine or pyrimethamine in pregnancy, so it is not known whether the current dosing is optimal. The absorption and disposition of many drugs are also altered in infancy, but there are very few data on antimalarial pharmacokinetics in the first year of life. For some drugs (e.g., amodiaquine) there is insufficient information for any age group.

Pharmacodynamics

Is the benefit of IPT gained only through clearing parasites from the placenta (“treatment effect”), or is the prevention of new infections (“prophylactic effect”) an important component? If only the treatment effect is important, then how long does the beneficial effect of eradicating an asymptomatic low-density infection persist for? If it lasts until the next infection becomes patent (i.e., detectable), then rapidly eliminated drugs will provide protection only for a few days longer than the average incubation period (about two weeks). Establishment of a new placental infection (i.e., pathologically significant placental sequestration) may take longer because the placenta selects and accumulates parasites that bind to the proteoglycans chondroitin sulphate and hyaluronidic acid [23]. If only the treatment effect is important, then for sustained benefit we must hypothesise that the parasites that persist asymptotically before IPT is given are a selected subpopulation that is more pathological than the parasites that cause subsequent reinfection. This seems implausible in infancy, and even in pregnancy it seems unlikely that it would take more than ten weeks in high-transmission settings to re-establish a significant placental infection. This suggests that the prophylactic effect is important for the efficacy of IPT.

The duration of prophylactic effect is compromised particularly by resistance. For most antimalarials the duration of antimalarial effect is a simple function of the in vivo concentration–effect (dose–response) relationship and the pharmacokinetic properties of the antimalarial drug [22]. But for SP this function is more complicated, as synergy between the two components needs to be considered. The duration of synergy depends on resistance levels determined by mutations in the parasites’ genes encoding dihydropteroate synthase and dihydrofolate reductase, the respective targets of sulphadoxine and pyrimethamine [20,21]. Information on this temporal pattern of reinfection following IPT in pregnancy or infancy is lacking. Such information is essential if the choice of drug and the dosing is to be rationalised.

Resistance is defined by a right shift in the concentration–effect relationship and results in reduced effects for any concentration below the MPC for resistant parasites [24] (see Figure 1). As the concentration of a slowly eliminated antimalarial in the blood declines, it continues to suppress the growth of newly acquired infections as they emerge from the liver. Eventually, however, concentrations fall below the minimum inhibitory concentration (MIC) for the prevalent parasites (i.e., the concentration at which the net multiplication rate is one), and parasite expansion is possible (Figure 3). It follows, then, that the duration of “post treatment prophylaxis” (PTP) (i.e., the length of time after an antimalarial treatment dose for which newly acquired infections are suppressed) is determined by the concentrations of the drugs used (determined by dose and pharmacokinetics) and the sensitivity of the prevalent parasites. The more resistant the parasites are, the shorter is the duration of PTP; for each doubling of MIC the duration of PTP is shortened by one half-life (Protocol S1). The triple dihydrofolate reductase mutants now prevalent across much of Africa have an approximate 1,000-fold reduction in pyrimethamine susceptibility, which would translate into a reduction in PTP of one month (Figure 4). As a further confounder, folic acid, which is prescribed widely in pregnancy, is a competitive antagonist of pyrimethamine.

Preventing Placental Pathology

In a high-transmission setting infections are acquired every few days or weeks throughout life (see Figure 3). Mortality is high in childhood, but by the time of adulthood and
pregnancy, infections are largely asymptomatic—although they are often still patent (which requires a total burden of greater than 100 million parasites) [22]. Thus, immunity prevents life-threatening parasite burdens, and suppresses the pro-inflammatory response (which causes illness), but it does not prevent infection.

In pregnancy this immune control is impaired in the placenta, which acts as a “privileged site” for parasite multiplication. The objective of IPT in pregnancy is to reduce or eliminate the adverse effects of malaria on maternal anaemia and birth weight, and, in addition, in a low-transmission setting, to prevent severe malaria in the mother [25,26]. How malaria produces intrauterine growth retardation is still unresolved, but in *P. falciparum* malaria, retardation tends to be greatest in the first pregnancy, and often occurs without maternal illness. The greater the placental parasite burden, the greater is the reduction in birth weight. “Placental malaria”—histological evidence of placental accumulation of parasitized erythrocytes or malaria pigment deposition—has often been used as an endpoint in intervention studies, although the quantitative relationship between placental malaria and reduction in birth weight remains poorly characterised.

**Preventing Malaria in Infancy**

There are fewer data on the efficacy of IPT in infancy than in pregnancy (Table S3). The pharmacodynamics of IPT in infancy are probably similar to those in pregnancy, although there is no “privileged site” for parasite multiplication. Protection in the first months of life is mediated by a variety of factors, which include transplacentally acquired maternal antibody (IgG) and a relatively high haemoglobin F content in the infants’ erythrocytes. After about six months of age, protection from these factors wanes, and the infant becomes much more vulnerable to malaria than the mother (because protective immunity has yet to be acquired). As delivery of antimalarials in the rural tropics is so difficult, for operational reasons IPT is currently being given to infants at the same time as the EPI immunisations (at 2, 3, and 9 months). This regimen leaves a six-month gap between the second and third administrations, which, even for fully SP-sensitive parasites, leaves four unprotected months. This is at a time when the infant is increasingly vulnerable to severe malaria. More information is needed on the duration of protection afforded by currently available antimalarial drugs when administered to healthy infants.

**Should IPT be Used in Low-Transmission Settings?**

If IPT is just a simple, albeit imperfect, way of administering chemoprophylaxis, then there are also strong arguments for evaluating this approach in low-transmission settings. The adverse impact of malaria in pregnancy is greater in low-transmission than in high-transmission settings. The reduction in the birth weight of first-borne infants is similar, but extends to the second and subsequent pregnancies; treatment failure rates are higher than in non-pregnant adults [27,28,29]; and there is a significant risk of severe malaria with attendant very high mortality. In Asia and South America, where low-transmission areas predominate, *P. vivax* is also an important cause of low birth weight, and so useful preventative measures must also be effective against this infection [30].

Antimalarial prophylaxis has been recommended and used in low-transmission settings, but whereas chloroquine remains generally effective against *P. vivax*, there are no safe and effective available drugs for *P. falciparum* infections. Use of IPT in these areas would provide a sterner test than in a high-transmission area because there would be little or no background immunity to assist antimalarial drug efficacy.

**What is the Correct Interval Between Doses?**

The dose used in IPT is usually the full age- or weight-adjusted treatment dose derived either empirically or from dose-finding studies (usually in non-pregnant adults). The dose and dosing interval should be determined by the tolerability, absorption, distribution, and elimination kinetics of the drug used, and the in vivo MIC. Unfortunately, for the two drugs that have been used for IPT (SP and amodiaquine) there are no pharmacokinetic data in pregnant women or infants. The in vivo MIC is an important measure but it is parasite specific and difficult to assess [31,32,33,34,35]. Ideally, the interval between doses should not be more than one week longer than the time needed for plasma concentrations to fall from peak post-dose levels to the MIC value. This timing is a conservative choice as it assumes all infections are equally harmful, and it does not take into account either the delay in selecting a placenta-binding *P. falciparum* subpopulation in pregnancy or the delay in achieving full growth rates because of continued sub-MIC suppression. Although the MIC for drugs that are succumbing to resistance obviously varies considerably, for newer drugs such as lumefantrine or piperaquine the variance is considerably less and generalisations can be made.

**Should an Artemisinin Combination Be Used for IPT?**

If IPT is simply prophylaxis, then a rapidly eliminated artemisinin...
are much lower than in acute symptomatic infection. But there is a genuine concern that if monotherapies are made available, then they will be used and abused, and resistance may develop.

**Discussion: The Policy Implications**

Without a better understanding of the pharmacodynamic effects of IPT, it will be difficult to make rational improvements in this promising approach to malaria prevention. The most parsimonious explanation for its effectiveness is that IPT provides antimalarial prophylaxis that, if sufficiently lengthy and effective, is beneficial both to the pregnant woman and the infant. But how lengthy and how effective?

For IPT in pregnancy the only drug that has been evaluated is SP, at a time when the drug was more effective than it is today. A significant improvement in birth weight was found in only two of four randomised trials. In a large prospective observational study conducted in western Kenya, IPT was associated with an odds ratio of 0.65 (95% confidence interval, 0.45 to 0.95) for low birth weight [7]. A dose–response relationship was found, with an adjusted mean increase in birth weight of 61 g for each increment in the number of SP doses (up to three doses). So, two doses of SP did not provide maximal benefit. But given the alarming decline in SP efficacy in Africa (resulting from rapid spread of “quintuple” dihydrofolate reductase/dihydropteroate synthase mutants that are about 1,000 times less sensitive to pyrimethamine than wild-type parasites), there are grave doubts about whether the efficacy observed in these various studies would still be observed today, even if the dosing was increased. SP cure rates in children in Malawi—where IPT in pregnancy is widely used—have been consistently less than 40% for the past five years [36]. It has been suggested that asymptomatic pregnant women in high-transmission settings may have sufficient immunity to complement a failing drug—i.e., treatment responses would be better than in symptomatic children.

However, if the duration of PTP is the main determinant of benefit, then this benefit is shortened progressively by increasing resistance (see Figure 4).

Alternatives to SP are needed urgently. Is IPT safe? There is no evidence to date that IPT is harmful. But the incidence of serious adverse effects when amodiaquine (agranulocytosis, 1:2,000) and SP (Stevens-Johnson syndrome, 1:7,000) were used as antimalarial prophylaxis by Western travellers was so high that they are contraindicated [37]. Both drugs were associated with severe hepatitis. Single treatments are considered safer, but how much safer is not known. There are insufficient data on the safety of amodiaquine in pregnancy [38].

The closer IPT comes to continuous prophylaxis, presumably the higher the risks of serious adverse effects. The risk–benefit assessment is difficult to make, but with the current high levels of SP resistance, these important uncertainties also argue strongly for the evaluation of alternatives. Proguanil component provides very little direct benefit for the additional cost and risk (although the risks are thought to be very small in the second and third trimesters of pregnancy and in infancy). The addition of an artemisinin component would accelerate parasite clearance and prevent gametocyte production, but the benefits of this in an asymptomatic pregnant woman or child are uncertain. The main benefit would be in providing protection against the emergence of de novo resistance to the slowly eliminated drug, although, because parasitaemias tend to be low, the probabilities of de novo selection for the additional cost and risk (although the risks are thought to be very small in the second and third trimesters of pregnancy and in infancy). The addition of an artemisinin component would accelerate parasite clearance and prevent gametocyte production, but the benefits of this in an asymptomatic pregnant woman or child are uncertain. The main benefit would be in providing protection against the emergence of de novo resistance to the slowly eliminated drug, although, because parasitaemias tend to be low, the probabilities of de novo selection fostered by IPT would be very small in the second and third trimesters of pregnancy and in infancy. The addition of an artemisinin component would accelerate parasite clearance and prevent gametocyte production, but the benefits of this in an asymptomatic pregnant woman or child are uncertain. The main benefit would be in providing protection against the emergence of de novo resistance to the slowly eliminated drug, although, because parasitaemias tend to be low, the probabilities of de novo selection.
and quinine are regarded as safe, but both are eliminated very rapidly. Treatment doses of mefloquine are not well tolerated by healthy subjects, and there are safety concerns in pregnancy [39].

Serious contenders all require more than a single dose and will need urgent evaluation. These include arteether-lumefantrine, although more information is needed on safety and on the pharmacokinetics in pregnancy, and the duration of PTP provided by lumefantrine needs further assessment. It may be too short. Dihydroartemisinin-piperaquine may be the most promising candidate. It is very well tolerated, and piperaquine is slowly eliminated. Indirect evidence from the pattern of new infections following clinical trials suggests protracted suppressive activity. It has not yet been evaluated in pregnancy, so more information is needed on safety and pharmacokinetics in this context. For IPT in infancy, however, there seems every reason to evaluate this drug as soon as possible. ■

Supporting Information

Protocol S1. Calculations Showing That for Each Doubling of MIC the Duration of PTP Is Shortened by One HalfLife

Found at DOI: 10.1371/journal.pmed.0020003.s001 (27 KB DOC).

Table S1. Randomised Trials of IPT in Pregnancy

Found at DOI: 10.1371/journal.pmed.0020003.s001 (31 KB DOC).

Table S2. Terminal Elimination Half-Lives of Currently Available Antimalarial Drugs

Found at DOI: 10.1371/journal.pmed.0020003.s002 (34 KB DOC).

Table S3. Randomised Trials of IPT in Infancy

Found at DOI: 10.1371/journal.pmed.0020003.s003 (27 KB DOC).

Acknowledgments

I am very grateful for advice from Francois Nosten, Feiko ter Kuile, Jane Crawley, Nick Day, and Bill Watkins. N. J. White is a Wellcome Trust Principal Fellow.

References

1. Schultz LJ, Steketee RW, Macheso A, Kazembe P, Chitoulo L, et al. (1994) The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 51: 515–522.

2. Verhoef FH, Brahin BJ, Chimisiku L, Kazembe P, Russell WB, et al. (1998) An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Ann Trop Med Parasitol 92: 141–150.

3. Parise ME, Ayisi JG, Nahlen BL, Schultz LJ, Roberts JM, et al. (1998) Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 59: 813–822.

4. Shulman CE, Dorman EK, Cutts F, Kawundu K, Bulner JN, et al. (1999) Intermittent sulfadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: A randomised placebo-controlled trial. Lancet 353: 652–656.

5. Ngari JR, Magunya P, Estambale B, Ouma J, Mugee B (2003) Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malaria prone area of Kenya: A randomised controlled trial. Trans R Soc Trop Med Hyg 97: 277–282.

6. Rogerson SJ, Chahaluka E, Kanjala M, Mkindika P, Mhango C, et al. (2000) Intermittent sulfadoxine-pyrimethamine in pregnancy: Effectiveness against malaria morbidity in Blantyre, Malawi, in 1997–99. Trans R Soc Trop Med Hyg 94: 549–553.

7. van Eijk AM, Ayisi JG, ter Kuile FO, Otieno JA, Msiore AO, et al. (2004) Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine for control of malaria in pregnancy in western Kenya: A hospital-based study. Trop Med Int Health 9: 351–360.

8. Guyatt HL, Noor AM, Ochola SA, Snow RW (2004) Use of intermittent presumptive treatment and insecticide treated bed nets by pregnant women in four Kenyan districts. Trop Med Int Health 9: 225–230.

9. Schellenberg D, Menendez C, Kahigwa E, Aponte J, Vidal J, et al. (2001) Intermittent treatment with pyrimethamine to control anaemia in children: A randomised, placebo-controlled trial. Lancet 357: 1471–1477.

10. Desa MR, Mei JY, Kuruki SK, Wannmuehler KA, Phillips-Howard PA, et al. (2003) Randomized, controlled trial of daily iron supplementation and intermittent sulfadoxine-pyrimethamine treatment of mild childhood anaemia in western Kenya. J Infect Dis 187: 658–666.

11. Massaga J, Kina YJ, Lennge MM, Akida JA, Malle LN, et al. (2003) Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: A randomised placebo-controlled trial. Lancet 361: 1853–1857.

12. Verhoef H, West CE, Nzyuko SM, de Vogel KS, van der Valk R, et al. (2002) Intermittent sulfadoxine-pyrimethamine for prevention of malaria in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malaria prone area of Kenya: A randomised controlled trial. Trans R Soc Trop Med Hyg 97: 277–282.

13. Mogendi D, Woodland M, Guthery WT (1964) Controlled trial of pyrimethamine in pregnancy in an African village. BMJ 1: 67–68.

14. Greenwood BM, Greenwood AM, Snow RW, Byass P, Bennett S, et al. (1989) The effects of malaria chemotherapy given by traditional birth attendants on the course and outcome of pregnancy. Trans R Soc Trop Med Hyg 83: 589–594.

15. Greenwood BM, Greenwood AM, Bradley AK, Snow RW, Byass P, et al. (1988) Comparison of two strategies for control of malaria within a primary health care programme in the Gambia. Lancet 1: 1121–1127.

16. Menendez C, Kahigwa E, Hiti R, Vounouam P, Aponte J, et al. (1997) Randomised placebo-controlled trial of iron supplementation and malaria chemotherapy for prevention of severe anaemia and malaria in Tanzanian infants. Lancet 350: 844–848.

17. Lennge MM, Msangeni HA, Renu AM, Salum FM, Jakobsen PH, et al. (1997) Maloprim malaria prophylaxis in children living in a holoendemic village in northeastern Tanzania. Trans R Soc Trop Med Hyg 91: 68–73.

18. Wolfe EB, Parise ME, Haddix AC, Nahlen BL, Ayisi JG, et al. (2001) Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. Am J Trop Med Hyg 64: 178–186.

19. Newman RD, Parise ME, Stukler L, Nahlen B, Sokette RW (2003) Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: Implications for prevention programmes in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health 8: 488–506.

20. Watkins WM, Mberu EK, Winstanley PA, Plowe CV (1997) The efficacy of antifolate antimalarial combinations in Africa: A predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 13: 459–464.

21. Watkins WM, Mberu EK, Winstanley PA, Plowe CV (1999) More on ‘the efficacy of antifolate antimalarial combinations in Africa’. Parasitol Today 15: 131–132.

22. White NJ (1997) Assessment of the pharmacodynamic properties of the antimalarial drugs in-vitro. Antimicrob Agents Chemother 41: 1413–1422.

23. Beeson JG, Brown GV (2004) Plasmodium falciparuminfected erythrocytes demonstrate dual specificity for adhesion to hyaluronic acid and chondroitin sulfate A and have distinct adhesive properties. J Infect Dis 189: 169–179.

24. White NJ (2004) Antimalarial drug resistance. J Clin Invest 113: 1084–1095.

25. Shulman CE, Dorman EK (2005) Importance and prevention of malaria in pregnancy. Trans R Soc Trop Med Hyg 97: 30–35.

26. Greenwood B (2004) ‘Therapeutic’ doses of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg 70: 7–7.

27. Nosten F, ter Kuile F, Maclennan L, Decluyt B, White NJ (1991) Malaria during pregnancy in an area of unstable endemicity. Trans R Soc Trop Med Hyg 85: 424–429.

28. McGregor R, Nosten F, de la Thai-Burmese border: Drug studies of Plasmodium falciparum in pregnancy. Ann Trop Parasitol 95: S10–S23.

29. McGregor R, Cho C, Ree NK, Thawii KL, Villegas L, et al. (2001) Artemisinin antimalarials in pregnancy: A prospective treatment study of 359 episodes of multidrug-resistant Plasmodium falciparum. Clin Infect Dis 33: 2009–2016.

30. Nosten F, McGregor R, Simpson JA, Thawii KL, Balkan S, et al. (1999) The effects of Plasmodium vivax malaria in pregnancy. Lancet 354: 546–549.

31. Hellgren U, Kihmama CM, Mahikcano IF, Bjorkman A, Eriksson O, et al. (1989) Response of Plasmodium falciparum to chloroquine treatment: Relation to whole blood concentrations of chloroquine and desethylchloroquine. Bull World Health Organ 67: 197–202.

32. Hellgren U, Kihmama CM, Bergqvist Y, Rombo L (1991) Standard and reduced doses of mefloquine for treatment of Plasmodium falciparum in Tanzania: Whole blood concentrations in relation to adverse reactions, in two response, and in vitro susceptibility. Am J Trop Med Hyg 45: 254–292.

33. Simpson JA Watkins ER, Price RN, Arons L, Kyle DE, et al. (2000) Mefloquine pharmacokinetic-pharmacodynamic models: Implications for dosing strategies. Antimicrob Agents Chemother 44: 3414–3424.

34. Svensson US, Alin H, Karlsson MO, Bergqvist Y,
Ashton M (2002) Population pharmacokinetic and pharmacodynamic modelling of arteisinin and mefloquine enantiomers in patients with falciparum malaria. Eur J Clin Pharmacol 58: 339–351.

35. Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, et al. (2003) Quinine pharmacokinetic pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother 47: 3458–3463.

36. Plowe CV, Kublin JG, Dzinjalamala FK, Kamwendo DS, Mukadam RA, et al. (2004) Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: Five year prospective study. BMJ 328: 545.

37. Taylor WR, White NJ (2004) Antimalarial drug toxicity: A review. Drug Saf 27: 25–61.

38. Thomas F, Erhart A, D’Alessandro U (2004) Can amodiaquine be used safely during pregnancy? Lancet Infect Dis 4: 235–239.

39. Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, et al. (1999) The effects of mefloquine treatment in pregnancy. Clin Infect Dis 28: 808–815.